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Abstract 
Globally there has been approximately 35 million deaths because of the human 
immunodeficiency virus (HIV) since the start of this epidemic and it is still an ongoing 
battle (WHO). Research continues in the hopes to stop this epidemic and the 
development of pre-exposure prophylaxis might be the key to this problem. Pre-
exposure prophylaxis--PrEP--is an HIV prevention tool that was approved by the U.S. 
Food and Drug Administration in 2012. It is an intervention tool developed for those who 
are at high risk of acquiring HIV. In my field experience, at the Kansas Department of 
Health and Environment, I was able to create a PrEP toolkit which consisted of 
educational materials for providers and consumers on PrEP. The overall goal of this 
field experience is for Kansans to have the opportunity to use PrEP as a prevention tool 
which may lead to a decrease of HIV cases per year in the state of Kansas.  
Furthermore, my capstone project focused on Alzheimer’s disease (AD) within 
the military population. Alzheimer’s disease is a neurodegenerative disease that is 
currently affecting more than five million Americans. The aging military veterans are one 
of the populations most affected with Alzheimer’s disease. Evidence suggest that this 
aging military population has potentially been subjected to additional risk factors 
compared to the general population. Consequently, it is believed that this population 
represents an elevated risk for AD and other dementias. Therefore, the goal of our 
study was to use existing statistical classification methods to be able to detect AD at an 
early stage and determine important biomarkers for the military population.  
 
Subject Keywords: human immunodeficiency virus (HIV), acquired immunodeficiency 
syndrome (AIDS), pre-exposure prophylaxis (PrEP), HIV prevention, Alzheimer’s 
disease (AD), veterans, traumatic brain injury (TBI), post-traumatic stress disorder 
(PTSD) 
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Chapter 1 - Kansas Department of Health & Environment: 
STI/HIV Section 
 Introduction 
At the end of 2013, there were approximately 1.2 million people in the United 
States living with human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) from the age of thirteen and older (Hiv/aids.2016). Furthermore, globally, 
there are approximately 36.7 million people who are currently living with HIV/AID 
(Global statistics.2016). HIV/AIDS is not something from the past, but it is an ongoing 
battle. There are many global and U.S. government agencies interested in decreasing 
the AIDs burden. AIDS.gov is one of the U.S. government agencies that focuses on 
increasing HIV testing, awareness, and access to Federal HIV information. Additionally, 
there are many state health departments that work with HIV prevention and with those 
individuals who are HIV-positive (HIV/AIDS: U.S. government agencies.2016).  
The Kansas Department of Health & Environment (KDHE) is one of those state 
health departments that possesses an STI/HIV sector. KDHE is comprised of the 
following three divisions: Public Health, Environment, and Health Care Finance (About 
KDHE.2016). I had the opportunity to work for the Bureau of Disease Control and 
Prevention under the division of Public Health. The Bureau of Disease Control and 
Prevention is composed of the following sectors: immunization, influenza information, 
STI/HIV, and tuberculosis. My preceptor, Stephanie Green, is the STI/HIV Section Chief 
for KDHE in Topeka, Kansas.  My project focused on the prevention of HIV by the use 
of pre-exposure prophylaxis (PrEP). Chapter two will focus on my project involving 
PrEP. 
 HIV Pathogenesis  
HIV gradually destroys the immune system by attacking CD4 +T cells, otherwise 
known as T-helper cells. These white blood cells are destroyed by HIV replication, thus-
not allowing CD4 cells to participate in protecting the body from infection (The HIV life 
cycle | understanding HIV/AIDS.2016). Dendritic cells bind to the HIV envelope 
glycoprotein gp120 with high affinity. This plays a crucial role in the initiation of HIV 
infection since this allows the virus to be presented to susceptible cells. HIV begins its 
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replication cycle when the virus binds to a CD4 molecule on the surface of a T cell 
(Fauci, 2007).  
The virus utilizes CD4 T cells to proliferate and spread to other parts of the body. 
Viral spread takes place in different stages, and begins with binding of the viral gp120 to 
the CD4 co-receptor. The glycoprotein undergoes conformational change to facilitate 
this binding and for fusion to occur. Fusion between the HIV envelope and the CD4 cell 
membrane then occurs, which allows for the establishment of the infection (Fauci, 
2007).  
Next, the virus converts viral RNA into DNA by using the HIV specific enzyme, 
reverse transcriptase. This gives the virus the ability to enter the host cell nucleus and 
insert its viral DNA into the DNA of the CD4 cells. Integration occurs with the release of 
an HIV specific enzyme, integrase.  This integration into the host DNA allows the virus 
to make long proteins chains by using the machinery of the CD4 cells. Then, these 
proteins translocate to the surface of the host cell along with HIV-RNA leading to the 
assembly of immature HIV virions, which are noninfectious. The immature HIV virions 
then bud out of the host cell. When virions bud out of the cell, the HIV enzyme protease 
is released. This enzyme breaks up the long protein chains that make up the immature 
virions into individual proteins. These individual proteins are recombined and they form 
a mature HIV, which is now infectious (The HIV life cycle | understanding 
HIV/AIDS.2016). Establishment of persistent and chronic infection occurs with 
spreading of virus to the gut-associated lymphoid tissues and other lymphoid tissues 
and organs.  There are multiple vital cellular and humoral responses during the initiation 
and the establishment of an HIV infection. HIV can escape the immune-mediated 
responses; therefore, this creates a persistent infection that cannot be eliminated 
completely (Fauci, 2007).  
HIV cannot be eliminated completely, but it can be controlled by focusing on 
preventive measures that help reduce the detectible viral load. The viral load refers to 
the amount of HIV present in a milliliter of blood. The CD4 cell count decreases as the 
viral load increases. Consequently, antiretroviral therapy (ART) is now used for many 
who are HIV-positive.  Antiretroviral treatment is used to decrease the viral load to 
almost undetectable levels in the blood. Studies have shown that reducing viral load can 
9 
 
also reduce the transmission rate (Prevention of mother-to-child transmission (PMTCT) 
of HIV | AVERT.2017; Fauci, 2007).  
 
  Epidemiology of HIV in Kansas  
The Kansas Department of Health and Environment in the Disease Control and 
Prevention Bureau emphasizes prevention. Their mission is: “To improve the quality 
and longevity of life for the citizens of Kansas by reducing the incidence of death and 
disability from infectious disease.”  According to KDHE, there are approximately 150 
people in Kansas being diagnosed with HIV each year (Kansas department of health 
and environment: STI/HIV section.2016). The spread of HIV is mostly found in the areas 
of Kansas City and Wichita, but there are several other cities in Kansas affected by this 
virus, such as Topeka in Shawnee County. Figure 1.1 is an image from KDHE HIV 
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report. It displays the number of people living with HIV by County in Kansas as of 
December 2016 (Kansas department of health and environment: STI/HIV section.2016).  
Figure 1.1 Number of People Living with HIV in the State of Kansas by County 
(2016)  
 
Men who have sex with men (MSM) is the population most affected by HIV. 
Black/African American MSM continue to experience a disproportionate increase of HIV 
diagnoses compared to Non-Hispanic White MSM (Pre-exposure prophylaxis 
(PrEP).2016). Figure 1.2 categorizes the routes of exposure for those who were newly 
diagnosed with HIV in Kansas from 2010-2014. 
 In the state of Kansas, there were 139 new cases of HIV diagnosed in 2014; 
2,827 HIV-positive people were known to live in the state of Kansas as of 2014 (Kansas 
department of health and environment: STI/HIV section.2016). Figure 1.3 is adapted 
from KDHE HIV report and it shows the incidence (those newly diagnosed with HIV in 
Kansas during that year) and prevalence (the total of all those living with HIV in Kansas) 
of HIV from 2010-2014. 
 
 
Figure 1.2 Incident HIV Cases by Exposure Category (2010-2014) 
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Figure 1.3 Incidence & Prevalence in Kansas (2010-2014) 
 
In Figure 1.3, there is a steady increase of prevalence each year. There are many 
factors that can play into this stable increase such as longer life expectancy. An aspect 
to consider is the development of antiretroviral therapy (ART). The prognosis of HIV-
positive individuals has improved drastically with the introduction of ART. ART has 
allowed for viral suppression making HIV a disease that can be controlled and no longer 
considered to be fatal. Studies show that early diagnosis of HIV and good adherence to 
antiretroviral drugs triggers higher life expectancies (Nakagawa et al., 2012).  
Furthermore, the incidence each year is stable and not significantly increasing or 
decreasing. This allows for more opportunities of infection since there is no significant 
decrease in incidence and there is a higher life expectancies leading to a higher 
prevalence. Therefore, Kansans should focus on preventive strategies such as pre-
exposure prophylaxis to significantly decrease the incidence each year. 
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Chapter 2 - Field Experience: Pre-Exposure Prophylaxis for 
HIV 
 Overview 
In 2012, Truvada® (a fixed-dose combination of emtricitabine and tenofovir 
disoproxil fumerate), an oral antiretroviral medication was approved by the U.S. Food 
and Drug Administration (FDA) as pre-exposure prophylaxis (Katz, 2013).  Pre-
exposure prophylaxis—PrEP—is used as an HIV prevention tool for those who are HIV 
uninfected, but are at a high risk of HIV acquisition (Hiv/aids.2016). The approval of 
PrEP was based on strong evidence from randomized clinical trials. In these clinical 
trials, all participants were given counseling on safer-sex behaviors and were given a 
regular supply of condoms. These participants were either given PrEP or a placebo and 
were regularly tested for STIs (Pre-exposure prophylaxis (PrEP).2016).  
The iPrEX (Pre-exposure Prophylaxis Initiative) trial was the first trial to produce 
valuable results and expose the idea that PrEP works. In this trial, 2,499 seronegative 
MSM and transgender women were given a combination of emtricitabine and tenofovir 
disproxil fumarate (FTC-TDF) or a placebo and were asked to be taken daily. There 
were 10 participants who were found to be HIV-positive at enrollment and 100 
participants tested HIV-antibody positive during follow-up. Among these 100 
participants, 64 occurred in the placebo group and 36 occurred in the FTC-TDF group; 
providing an efficacy of 44% (Grant et al., 2010).  
For the iPrEX trial, adherence was based upon self-report and the number of pills 
left in the bottles. This resulted to not be a reliable indicator of adherence. Drug levels 
were tested in those individuals that became infected with HIV and only drug levels 
were detected in 9% of those individuals. Since many of the subjects were not taking 
the drug as prescribed and the indicator of adherence was not reliable, researchers 
were able to calculate that the efficacy would have been at least 92% if participants 
would have taken the drug as prescribed (Grant et al., 2010). Altogether, in these 
clinical trials, higher adherence demonstrated lower HIV transmission for those 
individuals who took PrEP consistently. Present day, according to the CDC, PrEP is 
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known to help reduce the risk of getting HIV by 92% when used as prescribed (Pre-
exposure prophylaxis (PrEP).2016).  
PrEP is a prevention tool that should be taken every day to obtain high 
adherence. It is an effective prevention tool when combined with other preventive 
methods, such as condoms, and should not be a substitute for other safe sex practices. 
It is only recommended for those individuals that are uninfected since Truvada® is only 
one of the three medications prescribed for HIV-positive individuals (What is TRUVADA 
for PrEP.2017). If recently been exposed to the virus, post-exposure prophylaxis is to be 
used. Post-exposure prophylaxis—PEP—is used for those individuals who believe have 
been exposed to HIV within the past 72 hours and it involves taking the complete 
treatment of antiretroviral medications (Hiv/aids.2016). Therefore, PrEP requires regular 
testing to confirm that the individual is HIV-negative. Otherwise, the individual should be 
started on antiretroviral medications. The following are tests and evaluations necessary 
when starting on PrEP (What is TRUVADA for PrEP.2017):  
 Confirmed negative HIV-1 test 
 Creatinine test for creatinine clearance 
 HBV screening test 
 Confirm that the patient is not taking other HIV-1 or HBV medications 
 Pregnancy test- evaluate risk & benefits for a women who may be 
pregnant or may want to become pregnant 
 Ask about symptoms of acute HIV infection (flu-like symptoms)  
When starting PrEP the individual should be tested for STIs and HIV at least every three 
months.  
 Field Experience Objective  
The main objective of this field experience was to create a PrEP toolkit for 
providers that will eventually lead for Kansans to easily access PrEP as an HIV 
preventive intervention. This toolkit consists of educational information for providers in 
Kansas, but also for the current and future consumers. To fulfill this objective, I had to 
demonstrate an understanding of the following: the HIV virus and how it affects the 
body; HIV laboratory testing technology; PrEP and what it means for an individual to be 
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on PrEP; the CDC defined high-risk individuals and who are good candidates for PrEP; 
the STI/HIV Prevention Program at KDHE.  
 Activities Performed 
My field experience at KDHE consisted of completing multiple courses, 
conducting research, and producing resources for the implementation of PrEP in the 
state of Kansas. Figure 2.1 consists of an overview of all the activities performed at 
KDHE. The following information provides a more detailed overview of my field 
experience. 
During my field experience at KDHE, I completed the HIV 101 Course online via 
KS-Train to ensure a fundamental understanding of HIV. Additionally, via the National 
LGBT Health Education Center, I completed the following webinars: “Current Topics in 
HIV Pre-Exposure Prophylaxis (PrEP)” and “Preventing HIV with PrEP: A clinical 
update.” These webinars were led by a current physician that provides PrEP. The 
webinars provide a basic overview of PrEP, a clinical approach to common quandaries 
in PrEP management, and how to apply PrEP into clinical cases (Kevin L. Ard, 2016a; 
Kevin L. Ard, 2016b). These webinars will be accentuated to providers interested in 
prescribing PrEP. Providers will also receive an AAFP Prescribed credit for every 
webinar completed. This credit is accepted by many associations such as the American 
Medical Association and it equivalent to AMA PRA Category 1 Credit. These types of 
credits go towards the AMA Physician Recognition Rewards.   
Furthermore, my field experience consisted of developing educational materials 
for providers and consumers. To achieve this, I researched and reviewed the following: 
clinical trials conducted for PrEP, basic information about PrEP offered by the CDC and 
other well-recognized organizations, payment methods for PrEP (Truvada® ), and 
current reviews on PrEP. I also had the opportunity to work and interact with the 
Disease Intervention Specialists (DIS). The DIS assisted in gaining further 
understanding of the individuals at high-risk of STIs/HIV and implement this information 
when creating educational materials for potential consumers of PrEP.  
As a final point, we got approval for a PrEP tab to be added to the KDHE website 
under the Bureau of Disease Control and Prevention. Within this website, I added basic 
PrEP information and PrEP website links for providers and consumers. The educational 
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materials can be found on the website, and an order form can also be found for 
providers to order any more supplies needed from the toolkit provided. Likewise, I 
created a provider directory of all family medicine and infectious disease specialists 
practicing in Kansas by using Access. The directory provides general contact 
information of the providers and the addresses to send the toolkits. The anticipating 
goal is to add a provider resource directory to the website which outlines all the 
providers in Kansas that offer PrEP.   
 
 Implementing PrEP to at High-Risk Individuals  
Courses
• Completed HIV 101 Course online
• Completed the National LGBT Health Education Center 
webinars 
Research
• Basic information about PrEP
• Clinical trials conducted for PrEP
• How to pay for PrEP
• Current reviews on PrEP provided by consumers & providers 
• Recommendations from the DIS in Kansas 
Production 
• Created educational materials for providers & consumers
• Created a PrEP website for KDHE
• Created a provider directory 
Figure 2.1 Activities Performed at KDHE for the STI/HIV Section  
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HIV is lifelong disease and just one unsafe sexual behavior or action can lead to 
exposure to this virus. For this reason, it is important to recognized those individuals at 
high-risk of acquiring HIV and allowing them to access preventive care, such as PrEP. 
According to the CDC, there are roughly 1.2 million adults in the United States that 
could benefit from PrEP (Silapaswan, Krakower, & Mayer, 2017). The following are 
those individuals considered to be at high-risk(Pre-exposure prophylaxis (PrEP).2016): 
 Gay or bisexual man who have had anal sex without condoms 
 Those who use injection drugs 
 Those who have had an STI within the past 6 months 
 Those with an HIV-positive partner 
 Those with a partner who’s HIV status is unknown 
 Those who are not in a mutually monogamous relationship 
 Those who exchange sex for commodities 
PrEP is a preventive intervention; therefore, primary care providers should be 
prescribers of PrEP (Silapaswan et al., 2017). Primary care providers can play a vital 
role in identifying these individuals when conducting sexual histories in their practices. 
Conducting sexual histories gives providers access to their patients risk for STIs and 
HIV. This opens a window for risk-reduction counseling and potentially recognizing good 
candidates for PrEP. Unfortunately, studies have shown that less than 40% of providers 
conduct sexual histories in their practice (Lanier et al., 2014). Many of these providers 
state to not have received any formal type of training regarding sexual histories in 
school. For this reason, my project consisted of creating an educational sexual history 
brochure for providers in Kansas, which can be found in the appendix.  
 Many providers may avoid sexual histories since it may be uncomfortable for the 
provider and/or the patient. As stated in The Hidden Epidemic, “Ironically, it may require 
greater intimacy to discuss sex than to engage in it” (Thomas R. Eng, William T Butler, 
1997). Conducting a sexual history can be a challenge, but it is essential for being able 
to provide high-quality care. Figure 2.1 is an image of a sexual history form I was able to 
create for providers in the state of Kansas to have access to. The questions can easily 
be answered at any time. As a result, the patient can answer the questions before or 
during his or her appointment.   
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Additionally, it is important to not make any assumptions when conducting a 
sexual history. For example, I made question number 3 and 4 separate questions (3. 
“When was the last time you had sex with a male?” and 4. “When was the last time you 
had sex with a female?”) instead of combining the questions. Having them be separate 
questions gives 
the patient two 
opportunities to be 
sincere if he/she 
is sexually active 
with both males 
and females. Also, 
it gives the 
physician a better 
opportunity to 
catch these types 
of sexual 
behaviors.  
 
 
 
 
 
 
 
 
Lastly, KDHE has a Disease Intervention Program which focuses on intervening 
in the spread of STIs and HIV. Disease Intervention Specialists (DIS) work within the 
program in offering assistances with treatment to the infected individuals. The DIS is 
also in charge of contacting the patient that has been infected for further questioning 
(Kansas department of health and environment: STI/HIV section.2016). This helps 
Figure 2.2 Sexual History Form 
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identify those individuals that need testing and notify the partners of the infected 
individual.  
The DIS is constantly working with individuals at high-risk of getting HIV since it 
has been shown that people with an STI have a higher chance of acquiring HIV, when 
compared to people who do not have an STI (Hiv/aids.2016). Within the field 
experience, I was able to create labels for the DIS to hang in a custom-made lanyard. 
Figure 2.2 is an image of the labels made for the DIS. These labels consist of five 
different PrEP points, such as the possible side effects. The back of the label consists of 
different indicators that show if PrEP is right for his or her client.  
 
Correspondingly, figure 2.3 is an image of a patient referral card that folds into 
the size of a business card that I created for the DIS to handout to their clients. The 
labels that the DIS will carry will help in introducing PrEP to their clients, but the referral 
cards will offer continuation. The referral cards are meant for the clients to keep; this 
Figure 2.3 PrEP Labels for the Disease Intervention Specialist (DIS) 
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way they can refer to the card at any time. The client may not feel like he or she 
currently is not at high-risk of acquiring HIV, but that does not guarantee that it will 
change with time. For this reason, the information folds into a business card allowing for 
easy repository and access. The idea of the labels and referral cards was made with the 
contribution of the Tennessee Department of Health.   
 
 PrEP Toolkit 
Family medicine providers and infectious disease specialist will be given the 
opportunity to receive a PrEP toolkit. The materials provided in the toolkit can be found 
in the appendix. The following is the content found in the PrEP toolkit: 
 PrEP Brochure for Patients 
This brochure explains the basics of PrEP. It explains what PrEP is and who should take PrEP. It 
also offers information on programs that may help pay for PrEP. 
 PrEP Brochure for Providers 
This brochure explains the basics of PrEP and how Truvada® is currently the medication used for 
PrEP. It also explains some of the possible side effects and who are good candidates for PrEP.  
 PrEP Patient Referral Card (see figure 2.4) 
Figure 2.4 Referral Card 
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The card provides an explanation of what is PrEP. It also includes information on how to pay for 
PrEP 
 Why a Sexual History is Important Brochure 
This brochure consist of information on why it is important to conduct a sexual history and when a 
sexual history should be taken. It offers tips on how to conduct a sexual history.  
 Sexual History Patient Form (see figure 2.2) 
A sexual history form may use by providers to use for sexual histories.  
 Paying for PrEP Brochure 
This is a brochure provided by the CDC that shows different routes when it comes for covering the 
cost of PrEP.  
 CDC PrEP Posters 
These are 3 different PrEP posters offered by the CDC to promote and educated people on PrEP.   
 Truvada®  Medication Information Sheet (English & Spanish) 
This is an information for the patient for when he or she gets started on Truvada®. Gives an 
explanation on how to use the medication and some of the possible side effects.    
 Initiation of Truvada®:Checklist for Prescribers 
This is a checklist provided by Gilead Sciences, Inc. It is a checklist for providers to complete when 
prescribing Truvada®. It consist information on the labs and evaluations needed before prescribing 
Truvada®.   
 Taking a Pill Everyday Brochure 
This is brochure for providers to give to their patients when prescribing PrEP. It discusses the 
importance of taking PrEP every day.  
 Kansas Notifiable Disease Form 
This form should be used to report STI and HIV cases to the state of Kansas. When completed this 
forms need to be faxed to 785-559-4225. 
 Linkage to Care (LTC) Coverage Map 
The LTC programs was established to navigate newly diagnosed HIV-positive individuals into 
medical care. The map shows the different regions of the LTC program and their prospective 
coordinators.  
 Disease Intervention Specialists (DIS) Assignment Areas 
The DIS offers support services to providers, patients, and the public throughout the state of 
Kansas.  
 
Family medicine and infectious disease specialists will be contacted individually 
using the provider directory I created during my field experience. This directory is 
composed of over 400 providers in the state of Kansas. Contacting the provider will 
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permit us to know which providers are interested in receiving the toolkit and keeping 
them in our system. With time, we will arrange follow-ups with those providers that opt 
to receive the toolkit. These follow-ups are to indicate if the provider is prescribing PrEP 
or interested in receiving more information. The overall objective is to educate providers 
on PrEP and recruit them to offer and prescribe PrEP.  
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Chapter 3 - Early Detection of Alzheimer’s Disease in the 
Military Population 
 Introduction  
Alzheimer’s disease is the most common form of dementia. It is an irreversible 
and neurodegenerative disease. There are more than five million Americans living with 
Alzheimer’s disease and by 2050 it is estimated that this number will rise to 16 million 
(Alzheimer's disease facts and figures.2017). According to the Alzheimer’s Association, 
by the end of 2017, AD and other dementias will cost Americans 259 million dollars; it is 
estimated that these costs could rise as high as 1.1 trillion dollars by 2050. This makes 
it the most expensive disease in America and it cost more than heart disease and 
cancer (Alzheimer's disease facts and figures.2017). 
 From this rapidly increasing number of people being affected with AD, the aging 
military veterans are one of the populations most affected by it (Sibener et al., 2014). 
This is an important public health challenge and has become a priority for the military 
because of this the rapidly growing number of veterans be affected with AD and other 
dementias. The aging military population have been subjected to the same risk factors 
as the general population for AD and other dementias; but, evidence suggest that this 
population has potentially been subjected to additional risk factors compared to the 
general population. Therefore, it is believed that this population represents an elevated 
risk for AD and other dementias. Evidence suggest that some of the potential military 
risk factors include exposure to: a traumatic brain injury (TBI), post-traumatic stress 
disorder (PTSD), chemicals, such as pesticides, and lifestyle, such as depression that 
all eventually trigger the development of neurodegenerative diseases such as AD. 
Therefore, understanding this potential association has become a priority for the military 
since evidence show that these are common military risk factors for AD and other 
neurogenerative diseases (Khachaturian & Khachaturian, 2014).  
The goal of our study was to use existing statistical classifications methods to be 
able to detect AD at an early stage. In order to detect AD at an early stage, we needed 
to identify the most important biomarkers for the military population. The statistical 
methods used for this study were Su and Liu’s combination methods based on AUC 
23 
 
(area under the curve) and the stepwise method proposed by Kang et al (Kang, Liu, & 
Tian, 2016). The overall goal was to improve the classification rate of these biomarkers.  
The biomarkers considered for this study were the following: Mini-Mental State 
Exam (MMSE), the volume of hippocampus, the apolipoprotein gene (APOE ε4), TBI, 
and PTSD. Evidence indicate that these biomarkers are strong indicators of early 
stages of AD. The MMSE consist of a 30-point questionnaire and it is recommended for 
primary care physicians to use when evaluating older patients for cognitive impairments. 
It is used to estimate the progression of a cognitive impairment but it can have a low 
sensitivity when distinguishing between normal and mild cognitive impairment (MCI) 
(Trzepacz, Hochstetler, Wang, Walker, & Saykin, 2015). Additionally, loss of tissue 
throughout the brain and decreasing hippocampal volumes are characteristics 
associated with AD. Studies have shown that short-term memory loss results from the 
shrinkage of the hippocampus (Mu & Gage, 2011). Correspondingly, APOE ε4 is known 
to be a risk-factor gene since evidence show that it increases a person’s risk of 
developing AD (Alzheimer's disease facts and figures.2017; Petersen et al., 2010). 
Furthermore, an association of TBI with dementia has be found in studies involving the 
veteran and nonveteran populations. TBI consist of any injuring to the head from any 
external force. Also, the National Patient Care Database found that those individuals 
diagnosed with PTSD are twice more likely to develop dementia. Unlike TBI, PTSD is a 
psychological condition developed from the failure to recover from a distressing event 
(Weiner et al., 2013).  
 DOD ADNI Description  
For this project, data were obtained from the Department of Defense (DOD) 
Alzheimer’s Disease Neuroimaging Initiative (ADNI). ADNI was launched in 2003 and it 
is a longitudinal study that evaluates a range of biomarkers that could be used to 
measure the progression of AD (Jedynak et al., 2012). Some of these biomarkers 
include brain metrics derived from magnetic resonance imaging (MRI) and positron 
emission tomography (PET) scans, and blood, cerebrospinal fluid, and other biological 
markers (Braskie & Thompson, 2014).  The ADNI study consists of three phases: 
ADNI1, ADNI GO and ADNI2. New participants were added with each phase, but some 
were carried on from the previous phase to the new phase. 
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For our classification analysis, this project consisted of four biomarker profiles 
and each profile included the following three biomarkers: MMSE based on a scale of 24-
30; APOE ε4 based on the number of genes; hippocampal volumes measured with MRI. 
The second profile consisted of the three biomarkers in combination with TBI which was 
based on the number of TBI’s encountered during service. The third profile included the 
three biomarkers in combination with PTSD which was based on the Current Clinician 
Administered PTSD scale score. The final profile consisted of all five biomarkers 
combined. When the biomarkers were combined some of the data was lost. Table 3.1 
consists of a more detailed statistical description of the data.  
Biomarkers Sample 
size 
Mean Standard 
Deviation 
Missing Data 
Rates 
MMSE (scale 24-30) 441 28.84 1.38 7.03% 
Hippocampal Volumes 
(MRI scans) 
411 7251.08 987.29 0.24% 
APOE ε4 (number of 
genes) 
440 0.35 0.55 6.79% 
TBI (numbers encountered 
during service) 
69 1.64 1.64 83.25% 
PTSD (scale) 32 47.34 36.98 92.22% 
Table 3.1 Statistical Description of Biomarkers at Baseline  
 Statistical Analysis  
In classification studies, the area under the ROC curve (AUC) is the classification 
analysis typically used for biomarker selection and evaluation. A greater AUC indicates 
a stronger classifier, so the AUC for a strong classifier is closer to the value one than to 
zero.  The AUC is the most prevalent diagnostic accuracy index used by many 
researchers when combing multiple biomarkers into a single score (Yin & Tian, 2014). 
In our project, the AUC was calculated for all five biomarkers (MMSE, hippocampus, 
APOE ε4, TBI, and PTSD) using two different methods. The combination of these 
biomarkers was performed to obtain sufficient information for more accurate disease 
diagnosis. The biomarkers MMSE, APOE ε4, and the hippocampal volumes were the 
three biomarkers used for every profile. The methods were performed by using real data 
from the DOD ADNI for all those individuals that were classified as normal at baseline. 
Then these individuals were either classified as healthy (Nh) or diseased (Nd) if during 
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any follow-ups they were diagnosed with AD. The following were the two methods used 
to calculate the AUC for each profile:  
 Method 1: Su and Liu’s combination based on AUC (Kang et al., 2016) 
o This approach consists of a linear combination under the 
multivariate normality assumption. Under the assumption of 
normality, a large sample size is required for optimal results.  
 Method 2: Stepwise method proposed by Kang et al (Kang et al., 2016) 
o This is a nonparametric approach that maximizes the AUC by 
linearly combining markers by using a ‘distribution-free’ stepwise 
approach. 
We considered four biomarker profiles for the classification analyses. All the 
analyses were performed using R packages.  
 Results 
All biomarker profiles consisted of a high AUC using both methods. Comparing 
both methods (Su and Lui’s combination methods based on AUC and the stepwise 
method), the AUC were similar for all four biomarker profiles. The three biomarkers 
(MMSE, APOE ε4, and hippocampal volumes), TBI, and PTSD combined consisted of 
the highest AUC results compared to all the other profiles. The profile with the three 
biomarkers combined with the PTSD biomarker had the lowest AUC compared to all the 
other biomarkers. The three biomarkers combined with TBI had similar results 
compared to the profile with the three biomarkers alone. 
Column1 Column2 Column3 Column4 Column5  
3 
Biomarkers 
3 Biomarkers + 
TBI 
3 Biomarkers + 
PTSD 
3 Biomarkers+ TBI + 
PTSD  
Nh = 375 Nh = 57 Nh = 26 Nh = 12 
 
Nd = 37 Nd = 6 Nd = 5 Nd = 2 
   
AUC 
 
Method-1 0.8888 0.8567 0.8000 0.9583 
Method-2 0.8509 0.8567 0.8000 1.0000 
 
Table 3.2 The AUC of Various Biomarker Profiles using Two Classification Methods  
 Discussion  
26 
 
The results reveal that TBI is a stronger biomarker compared to PTSD. When 
PTSD was included in combination with MMSE, APOE ε4, and hippocampal volumes 
the AUC values decreased compared to when PTSD was not included. When TBI was 
included with the other three biomarkers the AUC was high using both methods. This is 
an indicator that TBI is a stronger biomarker compared to PTSD. The three biomarkers, 
TBI and PTSD, combined with MMSE, APOE ε4 and the hippocampal volumes had an 
exceptionally high AUC. This indicates that the combination of all biomarkers are strong 
indicators of AD. In this combination, the AUC reached up to 1 using method-2.  
 However, the sample size in this study was a crucial limitation encountered, since a 
large portion of the data was missing, specifically data for TBI and PTSD. This could 
have potential affected the AUC since one of the methods used is approached under 
the assumptions of normality.  
Furthermore, the three biomarkers (MMSE, APOE ε4, and hippocampal volumes) 
alone were also strong biomarkers for AD. This shows consistency with numerous 
literature reviews since these three biomarkers are frequently being used for the 
detection of AD in the general population (Alzheimer's disease genetics fact sheet.2017; 
Mu & Gage, 2011; Trzepacz et al., 2015).In addition to these biomarkers, covariates 
such as age and history of TBI could have enhanced the performance of these 
statistical methods.  In conclusion, having had a larger sample may improve the 
performance of these statistical methods. A possible way to overcome this limitation is 
by adapting existing imputations methods which can be used to input the missing values 
in our data. In a future study, this may allow us to re-evaluate the biomarkers of TBI and 
PTSD.   
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Chapter 4 - Master of Public Health Core Competencies  
The following core competencies were obtained and practiced for the completion 
of this report.  
Epidemiology- Introduction to epidemiology course clarified the terminology 
used at KDHE. For example, understanding incidence and prevalence of HIV in Kansas. 
This was useful since the overall goal for the implementation of PrEP is to reduce the 
incidence of HIV in Kansas. 
Environmental Health- This core competency introduced me to how social 
economics and poverty can play a role in the health of a community. Working with the 
DIS and creating educational materials for consumers evolved in having knowledge on 
the importance of these factors. For example, when creating educational materials for 
consumers, we had to determine those at high-risk and how to reach them.   
Fundamental Methods of Biostatistics- Fundamental understanding of 
biostatistics was essential for the completion of the capstone project.  The project 
consisted of knowing how to interpret the AD data and being able to discuss 
interpretations with my major professor. It also consisted of cleaning the data using SAS 
and having data management skills. 
Administration of Health Care Organizations- This course involved 
apprehending the general policies of health insurances in America. Knowing how to pay 
for PrEP and educating consumers on how to pay for PrEP was needed for the 
implementation of PrEP. This consisted of finding resources for those individuals who 
have health insurance and those without health insurance.  
Social and Behavioral Bases of Public Health- This competency was 
practiced in the implementation of PrEP. We looked at patterns of transmission in 
Kansas and risk factors for HIV. We will be implementing PrEP in Wichita, Topeka, 
Lawrence, Manhattan, and Junction City since these are the areas with higher numbers 
of reported HIV cases.  
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Chapter 5 - Conclusion  
My field experience at KDHE and my capstone project granted me the 
opportunity to adapt my education to real world experiences. For my capstone project, I 
had the opportunity to work with real data. This consisted of having permission granted 
to use the data from the ADNI committee of researchers. Furthermore, this project 
consisted of implementing data management knowledge, such as modifying and 
cleaning the data using SAS. This also included implementing statistical knowledge to 
analyze the data. The final step consisted of interpreting the results and identify the 
connotation of these results.  
Additionally, my field experience at KDHE helped me develop professional skills 
and activities practiced in state agencies. For example, I had to understand legal issues 
when asking for approval to add PrEP to the KDHE website. The website had to be 
approved by the director of the bureau, the IT department, and from the Secretary of 
State. At KDHE, I also had the opportunity to develop professional relationships with 
others at the Bureau. For example, the information for the educational materials for 
consumers enhanced after interacting with the DIS and asking for their opinions, since 
they are constantly working with individuals at high-risk of HIV. Overall, this interaction 
assisted in understanding certain health behaviors and what factors might influence 
those behaviors.  
Furthermore, as a public health professional, I encountered the significance of 
understanding health care insurances, such as Medicare. Having encountered this 
information during the Administration of Health Care Organizations course allowed me 
fully understand the assistance programs offered for patients with or without health 
insurance on how to pay for PrEP. Finally, within this field experience I learned to 
appreciate the significance of applying epidemiological principles to this project. 
Reviewing the epidemiology of HIV in Kansas granted me the opportunity to view the 
potential impact PrEP can have in decreasing the incidence for HIV in Kansas.  
In conclusion, my field experience and capstone project consisted of 
understanding the importance of applying knowledge gained within the program and 
applying it to the real-world experiences and work. Having this hands-on experience 
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helped me reassure that I chose the right career and I look forward to contributing in 
improving the health of others.   
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Appendix 
Appendix A: PrEP Brochure for Patients 
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Appendix B: PrEP Brochure for Providers 
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Appendix C: Sexual History Brochure for Providers  
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Appendix D: Linkage to Care (LTC) Coverage Map  
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Appendix E: Paying for PrEP Brochure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix F: CDC PrEP Posters 
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Appendix G: Truvada® Medication Information Sheet (English & Spanish)\ 
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Appendix H: Initiation of Truvada®: Checklist for Prescriber 
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Appendix I: Truvada®: Safety Information Fact Sheet for Prescribers    
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Appendix J: Taking a Pill Everyday Brochure  
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Appendix K: Kansas Notifiable Disease Form  
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Appendix L: Disease Intervention Specialist (DIS) Assignment Areas 
 
 
 
